Hong Kong IPO: WuXi Biologics to spin off contract research, manufacturing unit via US$520 million deal in biotech push

WuXi XDC, a 60 per cent-owned unit of WuXi Biologics, could raise as much as US$520 million, including excess share allotment, based on the top end of its IPO price range.

Related Keywords

Cainiao ,China General ,China ,Tuhu ,Guangdong ,Wuxi ,Jiangsu ,Hong Kong ,Nicolas Aguzin ,Morgan Stanley ,China International Capital Corp ,Midea Group ,Citigroup ,Goldman Sachs ,Cayman Inc ,Wuxi Biologics ,Hong Kong Exchanges ,Kong Listed Wuxi Apptec ,